NEWRON PHARMACEUT. EO-20 (NP5) — Cash Flow Quality Index
NEWRON PHARMACEUT. EO-20 (NP5) has a Cash Flow Quality Index of -1.11x as of December 2024. Operating cash flow of €-17.61 Million is below net income of €15.84 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore NP5 operating cash flow to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
NEWRON PHARMACEUT. EO-20 Cash Flow Quality Index (2024–2024)
Historical Cash Flow Quality Index for NEWRON PHARMACEUT. EO-20 across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check NEWRON PHARMACEUT. EO-20 investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for NEWRON PHARMACEUT. EO-20 (2024–2024)
Year-by-year earnings quality comparison for NEWRON PHARMACEUT. EO-20. For live market cap and the full company financial profile, see NP5 market cap overview.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -1.11x | €-17.61 Million | €15.84 Million | — |